Cargando…

Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer

BACKGROUND: Liquid biopsy offers a minimally invasive alternative to tissue-based evaluation of mutational status in cancer. The goal of the present study was to evaluate the aggregate performance of OncoBEAM RAS mutation analysis in plasma of colorectal cancer (CRC) patients at 10 hospital laborato...

Descripción completa

Detalles Bibliográficos
Autores principales:	García-Foncillas, Jesús, Tabernero, Josep, Élez, Elena, Aranda, Enrique, Benavides, Manuel, Camps, Carlos, Jantus-Lewintre, Eloisa, López, Rafael, Muinelo-Romay, Laura, Montagut, Clara, Antón, Antonio, López, Guillermo, Díaz-Rubio, Eduardo, Rojo, Federico, Vivancos, Ana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6288144/ https://www.ncbi.nlm.nih.gov/pubmed/30467411 http://dx.doi.org/10.1038/s41416-018-0293-5

Ejemplares similares

Comparison of the Clinical Sensitivity of the Idylla Platform and the OncoBEAM RAS CRC Assay for KRAS Mutation Detection in Liquid Biopsy Samples
por: Vivancos, Ana, et al.
Publicado: (2019)

Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients: an expert taskforce review
por: García-Foncillas, J, et al.
Publicado: (2017)

MicroRNAs: Promising New Antiangiogenic Targets in Cancer
por: Gallach, Sandra, et al.
Publicado: (2014)

Potential Non-Invasive Biomarkers for Early Diagnosis of Oral Squamous Cell Carcinoma
por: Dikova, Valentina, et al.
Publicado: (2021)

Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer
por: Grasselli, J, et al.
Publicado: (2017)

Routine Molecular Screening of Patients with Advanced Non-SmallCell Lung Cancer in Circulating Cell-Free DNA at Diagnosis and During Progression Using OncoBEAM(TM)EGFR V2 and NGS Technologies
por: Garcia, Jessica, et al.
Publicado: (2021)

Liquid Biopsy in Oral Cancer
por: Lousada-Fernandez, Fatima, et al.
Publicado: (2018)

Epigenetic Landscape of Liquid Biopsy in Colorectal Cancer
por: Rodriguez-Casanova, Aitor, et al.
Publicado: (2021)

Monitoring of RAS mutant clones in plasma of patients with RAS mutant metastatic colorectal cancer
por: Fernández Montes, A., et al.
Publicado: (2022)

CD5 and CD6 as immunoregulatory biomarkers in non-small cell lung cancer
por: Moreno-Manuel, Andrea, et al.
Publicado: (2020)

Liquid Biopsy in Endometrial Cancer: New Opportunities for Personalized Oncology
por: Muinelo-Romay, Laura, et al.
Publicado: (2018)

Liquid Biopsy for Monitoring EC Patients: Towards Personalized Treatment
por: Piñeiro-Pérez, Raquel, et al.
Publicado: (2022)

Clinicopathological Profiles Associated with Discordant RAS Mutational Status between Liquid and Tissue Biopsies in a Real-World Cohort of Metastatic Colorectal Cancer
por: Brozos-Vázquez, Elena, et al.
Publicado: (2023)

TMPRSS4: A Novel Tumor Prognostic Indicator for the Stratification of Stage IA Tumors and a Liquid Biopsy Biomarker for NSCLC Patients
por: Villalba, Maria, et al.
Publicado: (2019)

Cancer Epigenetic Biomarkers in Liquid Biopsy for High Incidence Malignancies
por: Palanca-Ballester, Cora, et al.
Publicado: (2021)

MicroRNA profiling associated with non-small cell lung cancer: next generation sequencing detection, experimental validation, and prognostic value
por: Gallach, Sandra, et al.
Publicado: (2017)

On the Oral Microbiome of Oral Potentially Malignant and Malignant Disorders: Dysbiosis, Loss of Diversity, and Pathogens Enrichment
por: Herreros-Pomares, Alejandro, et al.
Publicado: (2023)

Serum metabolomic profiling facilitates the non-invasive identification of metabolic biomarkers associated with the onset and progression of non-small cell lung cancer
por: Puchades-Carrasco, Leonor, et al.
Publicado: (2016)

Current Status and Future Perspectives of Liquid Biopsy in Small Cell Lung Cancer
por: Mondelo-Macía, Patricia, et al.
Publicado: (2021)

Reporting reimbursement price decisions for onco-hematology drugs in Spain
por: Elvira, David, et al.
Publicado: (2023)

Biological insights in non-small cell lung cancer
por: Rosell, Rafael, et al.
Publicado: (2023)

Characterization of Circulating T Cell Receptor Repertoire Provides Information about Clinical Outcome after PD-1 Blockade in Advanced Non-Small Cell Lung Cancer Patients
por: Dong, Ning, et al.
Publicado: (2021)

Onco-immunomodulatory properties of pharmacological interference with RAS-RAF-MEK-ERK pathway hyperactivation
por: Avery, Thomas Yul, et al.
Publicado: (2022)

Top-ten infections in onco-hematological patients (2015-2017)
por: Camps, Isabel Ruiz, et al.
Publicado: (2019)

Single‐Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial)
por: García‐Alfonso, Pilar, et al.
Publicado: (2018)

NGS‐based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment
por: Sánchez‐Herrero, Estela, et al.
Publicado: (2021)

Biosensors for the Detection of Circulating Tumour Cells
por: Costa, Clotilde, et al.
Publicado: (2014)

Rational design of cancer gene panels with OncoPaD
por: Rubio-Perez, Carlota, et al.
Publicado: (2016)

Impact of DLK1-DIO3 imprinted cluster hypomethylation in smoker patients with lung cancer
por: Molina-Pinelo, Sonia, et al.
Publicado: (2016)

Controversies in the treatment of RAS wild-type metastatic colorectal cancer
por: Vera, R., et al.
Publicado: (2020)

Analysis of the immune microenvironment in resected non-small cell lung cancer: the prognostic value of different T lymphocyte markers
por: Usó, Marta, et al.
Publicado: (2016)

Analysis of the Gut Microbiota: An Emerging Source of Biomarkers for Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer
por: Zhang, Feiyu, et al.
Publicado: (2021)

Clinical Application of Circulating Tumour Cells in Prostate Cancer: From Bench to Bedside and Back
por: León-Mateos, Luis, et al.
Publicado: (2016)

Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients
por: Vidal, J, et al.
Publicado: (2017)

Identification of a novel synthetic lethal vulnerability in non-small cell lung cancer by co-targeting TMPRSS4 and DDR1
por: Villalba, Maria, et al.
Publicado: (2019)

Impact of circulating tumor DNA mutant allele fraction on prognosis in RAS‐mutant metastatic colorectal cancer
por: Elez, Elena, et al.
Publicado: (2019)

Public Perceptions of the Role of Lifestyle Factors in Cancer Development: Results from the Spanish Onco-Barometer 2020
por: Petrova, Dafina, et al.
Publicado: (2021)

Inhibition of α(1,6)fucosyltransferase: Effects on Cell Proliferation, Migration, and Adhesion in an SW480/SW620 Syngeneic Colorectal Cancer Model
por: López-Cortés, Rubén, et al.
Publicado: (2022)

PyOncoPrint: a python package for plotting OncoPrints
por: Park, Jeongbin, et al.
Publicado: (2023)

Improving the Management of Endometrial Cancer Patients through the Use of Liquid Biopsy Analyses: A Case Report
por: Casas-Arozamena, Carlos, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_69j9fh1k316jgbdc9jhp8dcl6i